| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
6,983 |
5,959 |
$912K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
4,655 |
4,027 |
$458K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,405 |
1,274 |
$256K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
3,552 |
2,938 |
$125K |
| G0378 |
Hospital observation service, per hour |
260 |
175 |
$65K |
| 80053 |
Comprehensive metabolic panel |
8,287 |
6,750 |
$41K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
8,838 |
6,993 |
$25K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
7,920 |
5,871 |
$23K |
| 71045 |
Radiologic examination, chest; single view |
4,006 |
3,478 |
$19K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
962 |
525 |
$18K |
| 81001 |
|
2,723 |
2,445 |
$10K |
| 70450 |
Computed tomography, head or brain; without contrast material |
1,695 |
1,524 |
$9K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
228 |
200 |
$7K |
| 84484 |
|
3,389 |
2,767 |
$6K |
| 71046 |
Radiologic examination, chest; 2 views |
391 |
358 |
$6K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
356 |
335 |
$5K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
105 |
95 |
$4K |
| 83690 |
|
2,469 |
2,227 |
$3K |
| 84703 |
|
782 |
682 |
$2K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
101 |
80 |
$2K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
75 |
64 |
$2K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
97 |
90 |
$2K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
96 |
85 |
$2K |
| 82553 |
|
540 |
441 |
$1K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
2,571 |
2,136 |
$1K |
| 83735 |
|
3,070 |
2,660 |
$1K |
| 83880 |
|
765 |
707 |
$1K |
| 82550 |
|
1,936 |
1,695 |
$1K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
505 |
459 |
$783.96 |
| 93971 |
|
25 |
24 |
$706.96 |
| 85610 |
|
1,700 |
1,525 |
$531.41 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
501 |
421 |
$415.13 |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
51 |
50 |
$394.19 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
719 |
529 |
$379.95 |
| 87088 |
|
190 |
178 |
$345.83 |
| 87077 |
|
84 |
76 |
$339.16 |
| 81003 |
|
569 |
504 |
$295.14 |
| 85027 |
|
124 |
101 |
$291.50 |
| 85730 |
|
1,053 |
946 |
$260.25 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
94 |
81 |
$164.86 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,000 |
1,671 |
$144.23 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
32 |
26 |
$104.70 |
| 87040 |
|
41 |
40 |
$89.61 |
| 83605 |
|
251 |
224 |
$66.59 |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
509 |
452 |
$64.95 |
| 85379 |
|
69 |
68 |
$58.80 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
158 |
140 |
$45.62 |
| 94760 |
|
14 |
12 |
$36.28 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
363 |
277 |
$27.79 |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
15 |
13 |
$24.03 |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
29 |
29 |
$22.41 |
| J2704 |
Injection, propofol, 10 mg |
249 |
197 |
$10.57 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
81 |
75 |
$2.45 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
45 |
36 |
$0.00 |
| J7050 |
Infusion, normal saline solution, 250 cc |
607 |
394 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
29 |
27 |
$0.00 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
25 |
24 |
$0.00 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
14 |
14 |
$0.00 |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
15 |
14 |
$0.00 |
| 0270 |
|
26 |
24 |
$0.00 |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
40 |
36 |
$0.00 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
62 |
54 |
$0.00 |
| 87186 |
|
28 |
25 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
22 |
18 |
$0.00 |